Trends in the Incidence, Treatment and Outcomes of Patients with Intrahepatic Cholangiocarcinoma in the USA: Facility Type is Associated with Margin Status, Use of Lymphadenectomy and Overall Survival

IntroductionIntrahepatic cholangiocarcinoma (ICC) remains an uncommon disease with a rising incidence worldwide. We sought to identify trends in therapeutic approaches and differences in patient outcomes based on facility types.MethodsBetween January 1, 2004, and December 31, 2015, a total of 27,120 patients with histologic diagnosis of ICC were identified in the National Cancer Database and were enrolled in this study.ResultsThe incidence of ICC patients increased from 1194 in 2004 to 3821 in 2015 with an average annual increase of 4.16% (p<0.001). Median survival of the cohort improved over the last 6 years of the study period (2004-2009: 8.05months vs. 2010-2015: 9.49months; p<0.001). Among surgical patients (n=5943, 21.9%), the incidence of R0 resection, lymphadenectomy and harvest of 6 lymph nodes increased over time (p<0.001). Positive surgical margins (referent R0: R1, HR 1.49, 95% CI 1.24-1.79, p<0.001) and treatment at community cancer centers (referent academic centers; HR 1.24, 95% CI 1.04-1.49, p=0.023) were associated with a worse prognosis. Patients treated at academic centers had higher rates of R0 resection (72.4% vs. 67.7%; p=0.006) and lymphadenectomy (55.6% vs. 49.5%, p=0.009) versus community cancer centers. Overall survival was also better at academic versus community cancer programs (median OS: 11monthsversus 6months, respectively; p<0.001).ConclusionsThe incidence of ICC has increased over the last 12years in the USA with a moderate improvement in survival over time. Treatment at academic cancer centers was associated with higher R0 resection and lymphadenectomyrates, as well as improved OS for patients with ICC.